Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$17.51 USD
-0.05 (-0.28%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $17.52 +0.01 (0.06%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CPRX 17.51 -0.05(-0.28%)
Will CPRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Other News for CPRX
Catalyst Pharmaceuticals enters exclusive agreement with Kye Pharmaceuticals
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
Catalyst sells Canadian rights to Duchenne drug to Kye Pharma
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX): A Growth-Oriented Value Investment Opportunity